MX2014002967A - Antagonistas de los productos del agrupamiento de unigenes hs.459642 para la inhibicion de la proliferacion, del desarrollo o de la diferenciacion de las celulas madre incluyendo las celulas madre cancerosas. - Google Patents

Antagonistas de los productos del agrupamiento de unigenes hs.459642 para la inhibicion de la proliferacion, del desarrollo o de la diferenciacion de las celulas madre incluyendo las celulas madre cancerosas.

Info

Publication number
MX2014002967A
MX2014002967A MX2014002967A MX2014002967A MX2014002967A MX 2014002967 A MX2014002967 A MX 2014002967A MX 2014002967 A MX2014002967 A MX 2014002967A MX 2014002967 A MX2014002967 A MX 2014002967A MX 2014002967 A MX2014002967 A MX 2014002967A
Authority
MX
Mexico
Prior art keywords
stem cells
antagonists
proliferation
differentiation
development
Prior art date
Application number
MX2014002967A
Other languages
English (en)
Inventor
Lloyd S Gray
Original Assignee
Tau Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tau Therapeutics Llc filed Critical Tau Therapeutics Llc
Publication of MX2014002967A publication Critical patent/MX2014002967A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Abstract

La presente descripción proporciona los métodos y las composiciones para inhibir la proliferación, la diferenciación, o el desarrollo de las células madre y de las células madre cancerosas en un paciente en necesidad de los mismos. Los métodos implican administrar a un paciente la cantidad terapéuticamente eficaz de un antagonista de un producto del agrupamiento de unigenes Hs.459642, como un inhibidor de CACNA1H. Las composiciones incluyen un antagonista de un producto del agrupamiento de unigenes Hs.459642, como un inhibidor de CACNA1H. Esta descripción también proporciona los antagonistas específicos como los anticuerpos y los oligonucleótidos antisentido, y la terapia de combinación con uno o más agentes anticáncer adicionales. Tales métodos, antagonistas, y composiciones pueden ser útiles, por ejemplo, en el tratamiento del cáncer.
MX2014002967A 2011-09-12 2012-09-11 Antagonistas de los productos del agrupamiento de unigenes hs.459642 para la inhibicion de la proliferacion, del desarrollo o de la diferenciacion de las celulas madre incluyendo las celulas madre cancerosas. MX2014002967A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161533545P 2011-09-12 2011-09-12
PCT/US2012/054567 WO2013039859A1 (en) 2011-09-12 2012-09-11 Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells

Publications (1)

Publication Number Publication Date
MX2014002967A true MX2014002967A (es) 2015-04-13

Family

ID=47830014

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002967A MX2014002967A (es) 2011-09-12 2012-09-11 Antagonistas de los productos del agrupamiento de unigenes hs.459642 para la inhibicion de la proliferacion, del desarrollo o de la diferenciacion de las celulas madre incluyendo las celulas madre cancerosas.

Country Status (12)

Country Link
US (2) US20130064814A1 (es)
EP (1) EP2755674A4 (es)
JP (1) JP2014526475A (es)
KR (1) KR20140084034A (es)
CN (1) CN103957923B (es)
AU (1) AU2012309800B2 (es)
CA (1) CA2848311A1 (es)
HK (1) HK1200120A1 (es)
IL (1) IL231385A0 (es)
MX (1) MX2014002967A (es)
SG (2) SG11201400526TA (es)
WO (1) WO2013039859A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX360640B (es) 2010-03-01 2018-11-09 Tau Therapeutics Llc Star Diagnosis e imagenologia de cancer.
JP2017031059A (ja) 2014-01-29 2017-02-09 学校法人慶應義塾 がん幹細胞の増殖抑制剤および細胞内活性酸素蓄積誘導剤
JP6876502B2 (ja) * 2016-04-25 2021-05-26 クラシエホールディングス株式会社 未分化細胞除去剤
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2018058489A1 (zh) * 2016-09-30 2018-04-05 武汉华大吉诺因生物科技有限公司 Cacna1h衍生的肿瘤抗原多肽及其应用
WO2019103578A1 (ko) * 2017-11-27 2019-05-31 (주)프로스테믹스 올리고뉴클레오티드 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
CA3127871A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
TR199801581T2 (xx) 1996-02-14 1998-10-21 Isis Pharmaceuticals, Inc. �ekerle de�i�tirilmi� bo�luklu oligon�kleotid'ler.
US6251886B1 (en) * 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
DE60322509D1 (de) 2002-01-17 2008-09-11 Univ British Columbia Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung
AU2005211764B2 (en) * 2004-02-11 2011-07-21 University Of Virginia Patent Foundation Inhibiting CAV3 isoforms and the delta25B splice varients for the diagnosis and treatment of cancer
US7662240B2 (en) * 2004-06-22 2010-02-16 The Timken Company Seal for worm gear speed reducer
KR100743255B1 (ko) 2006-05-04 2007-07-27 한국과학기술연구원 Ｔ-형 칼슘 채널에 활성을 지닌 신규1,3-다이옥소아이소인돌 유도체
SG10201503407WA (en) * 2006-12-19 2015-06-29 Genentech Inc Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
WO2009036059A2 (en) * 2007-09-10 2009-03-19 Boston Biomedical, Inc. Novel stat3 pathway inhibitors and cancer stem cell inhibitors
MY155603A (en) * 2008-07-08 2015-11-13 Oncomed Pharm Inc Notch-binding agents and antagonists and methods of use thereof
MX344725B (es) * 2009-06-05 2017-01-05 Tau Therapeutics Llc * Metodo entrelazado para tratar cancer o una condicion precancerosa.

Also Published As

Publication number Publication date
AU2012309800A1 (en) 2014-05-01
WO2013039859A1 (en) 2013-03-21
SG10201601917XA (en) 2016-04-28
KR20140084034A (ko) 2014-07-04
EP2755674A1 (en) 2014-07-23
SG11201400526TA (en) 2014-04-28
CN103957923B (zh) 2018-05-25
CA2848311A1 (en) 2013-03-21
US20200197516A1 (en) 2020-06-25
CN103957923A (zh) 2014-07-30
JP2014526475A (ja) 2014-10-06
HK1200120A1 (en) 2015-07-31
US20130064814A1 (en) 2013-03-14
EP2755674A4 (en) 2015-04-08
IL231385A0 (en) 2014-04-30
AU2012309800B2 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
MX2014002967A (es) Antagonistas de los productos del agrupamiento de unigenes hs.459642 para la inhibicion de la proliferacion, del desarrollo o de la diferenciacion de las celulas madre incluyendo las celulas madre cancerosas.
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
PH12015502575B1 (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
MX2013004491A (es) Boronatos como inhibidores de arginasa.
MD20150035A2 (ro) Inhibitori de tirozinkinaza Bruton
MX2016008201A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
TN2015000368A1 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
NZ700928A (en) Dna-pk inhibitors
MX2013008192A (es) Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
MD4590C1 (ro) Derivaţi macrociclici pentru tratamentul bolilor proliferative
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MX344335B (es) Derivados de benzonitrilo como inhibidores de cinasa.
MY191358A (en) Triazolopyrazines as brd4 inhibitors for use in the treatment of cancer
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
MX347765B (es) Inhibidores macrociclicos de la quinasa flt3.
MX2014013090A (es) Derivados de pirrolotriazinona.
MX362939B (es) Derivados de (aza-)isoquinolinona.
MX342257B (es) Derivados y análogos de oxaspiro [2.5] octano.
SG10201805392YA (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
MX2013010524A (es) Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata.
MX2016001536A (es) Derivados de urea de piperidinas.
GB201115977D0 (en) Neurodevelopmental disorders
UA33293U (ru) Способ лечения хронического эндометрита
TN2013000012A1 (en) New aminopyrazoloquinazolines